Invex Therapeutics (ASX:IXC) Quick Ratio : 12.22 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Invex Therapeutics's quick ratio for the quarter that ended in Dec. 2024 was 12.22.

Invex Therapeutics has a quick ratio of 12.22. It generally indicates good short-term financial strength.

The historical rank and industry rank for Invex Therapeutics's Quick Ratio or its related term are showing as below:

ASX:IXC' s Quick Ratio Range Over the Past 10 Years
Min: 6.38 Med: 20.33 Max: 53.08
Current: 12.22

During the past 5 years, Invex Therapeutics's highest Quick Ratio was 53.08. The lowest was 6.38. And the median was 20.33.

ASX:IXC's Quick Ratio is ranked better than
84.76% of 1496 companies
in the Biotechnology industry
Industry Median: 3.4 vs ASX:IXC: 12.22

Invex Therapeutics Quick Ratio Historical Data

The historical data trend for Invex Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics Quick Ratio Chart

Invex Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Jun24

Quick Ratio

13.11

49.68

29.37

14.51

14.17

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Quick Ratio	Get a 7-Day Free Trial						22.29	14.51	6.38	14.17	12.22

Competitive Comparison of Invex Therapeutics's Quick Ratio

For the Biotechnology subindustry, Invex Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's Quick Ratio falls into.

Save Embed

;

Save Embed

;

Invex Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Invex Therapeutics's Quick Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Quick Ratio (A: Jun. 2023 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(22.804	-	0)	/	1.572
	=	14.51

Invex Therapeutics's Quick Ratio for the quarter that ended in Dec. 2024 is calculated as

Quick Ratio (Q: Dec. 2024 )	=	(Total Current Assets	-	Total Inventories)	/	Total Current Liabilities
	=	(5.864	-	0)	/	0.48
	=	12.22

Invex Therapeutics (ASX:IXC) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.

Invex Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Quick Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.